In phase 3 studies, alemtuzumab demonstrated efficacy and safety in patients with relapsing-remitting multiple sclerosis. In an interview with touchNEUROLOGY, Prof. Bart Van Wijmeersch (Universiteit Hasselt and Rehabilitation and MS-Centre Pelt, Belgium) talks through the aims of the alemtuzumab post-authorization safety study, key findings, and insights gained regarding duration of monitoring following treatment with alemtuzumab for multiple sclerosis.
- What are the aims of the alemtuzumab post-authorization safety study and what period, post-first exposure, will it cover? (00:18)
- What are the key findings from this interim analysis? (00:48)
- What insight has been gained regarding the necessary duration of monitoring following treatment with alemtuzumab for multiple sclerosis? (01:46)
- Have any risk factors for experiencing treatment-related adverse events with alemtuzumab been identified? (02:47)
The abstract titled ‘Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)’ (Abstract #EPR-165) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Bart Van Wijmeersch has received grant/research support from Merck, Sanofi-Genzyme and participated in advisory boards from Almirall, Actelion/Janssen, Bayer, Biogen, Celgene/BMS, Imcyse, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
Share this Video
Related Videos In Multiple Sclerosis
Nele Handwerker: Living with MS – living life to the full
Ms Nele Handwerker is living with multiple sclerosis (MS), and is a patient advocate. She joins us for World Brain day and shares the story of her MS diagnosis. Nele discusses strategies and resources that she believes could help improve quality of life for those living with MS. Touch Medical Media is sharing educational resources […]
Barbara Willekens, EAN 2022: Predictors of disease progression and outcome in multiple sclerosis – Highlights
Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors and outcomes in MS and related disorders. Questions: How does cognitive impairment predict physical […]
Melinda Magyari, EAN 2022: Real-world evidence for disease-modifying therapies in multiple sclerosis
Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of real-world data, how ‘big data’ can help physicians understand treatment characteristics, and the future impact […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!